AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8262820
Drug: LSA2L2 chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSA2L2 chemotherapy with 1800 cGy cranial irradiation and 1500 cGy to nonabdominal bulk disease
Trial: 22222856
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg BHT-3009
Trial: 22222856
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg BHT-3009
Trial: 18567749
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg isoflavones (ISO)
Trial: 14643954
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) with a fraction dose of 1.8 Gy to a median total dose of 54 Gy
Trial: 1657199
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (0.15 mg)
Trial: 6401510
Drug: Long-term maintenance
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term maintenance treatment with cimetidine
Trial: 26883504
Drug: Self-management intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management intervention (home-based exercise program 3 times a week + physical therapy once every 2 weeks for 14 weeks)
Trial: 26883504
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care physical therapy (physical therapy twice a week + home-based exercise program once a week for 14 weeks)
Trial: 25028463
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (RHZE thrice weekly)
Trial: 7539544
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg hyoscine N-butyl bromide
Trial: 1970460
Drug: Nifedipine 1
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 1 mg i.v. with atracurium
Trial: 1970460
Drug: Nifedipine 1
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 1 mg i.v. during continuous relaxation with atracurium or vecuronium
Trial: 1970460
Drug: Nifedipine 1
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 1 mg i.v. at the end of anesthesia
Trial: 7019558
Drug: Timolol ophthalmic
RxNorm normalized name: timolol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol ophthalmic solution (0.1% - 0.5%)
Trial: 28651793
Drug: IM+oral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM+oral therapy (intramuscular + daily oral)
Trial: 28651793
Drug: Daily oral-only
RxNorm normalized name: Daily Hist Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral-only therapy
Trial: 21866096
Drug: GSK1018921 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1018921 (0.5 to 280 mg)
Trial: 19265025
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin daily for 6 weeks, then 20 mg from weeks 6 to 12
Trial: 19265025
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg atorvastatin daily for 6 weeks, then 20 mg from weeks 6 to 12
Trial: 19265025
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 6 weeks, then 20 mg rosuvastatin from weeks 6 to 12
Trial: 9574890
Drug: High allergen
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High allergen content NRL gloves with skin protection cream
Trial: 9574890
Drug: Low allergen
RxNorm normalized name: Black Willow Allergen Extract 0.05 GM/1 ML Subcutaneous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low allergen content NRL gloves with skin protection cream
Trial: 8166094
Drug: Manual toothbrushing
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrushing with standard fluoride toothpaste and daily use of a 0.05% sodium fluoride rinse
Trial: 29630721
Drug: Yimitasvir phosphate
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yimitasvir phosphate 30 mg
Trial: 29630721
Drug: Yimitasvir phosphate
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yimitasvir phosphate 100 mg
Trial: 29630721
Drug: Yimitasvir phosphate
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yimitasvir phosphate 200 mg
Trial: 21514589
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol esters (3.0 g/d)
Trial: 14730218
Drug: Clarithromycin (CAM)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (CAM) 400 mg/day orally for 14 days prior to surgery and for 7 days following surgery, in addition to flomoxef
Trial: 14730218
Drug: Flomoxef (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flomoxef (control group) administered for 4-7 days following surgery
Trial: 10150185
Drug: Trimetazidine 1
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 1 mg.kg‐1
Trial: 10150185
Drug: Trimetazidine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 1.5 mg.kg‐1
Trial: 3067546
Drug: CV 205-502
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CV 205-502 (0.05 micrograms daily)
Trial: 23832397
Drug: MSC1992371A administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC1992371A administered on days 1 and 8 (schedule 1)
Trial: 23832397
Drug: MSC1992371A administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC1992371A administered on days 1, 2, and 3 (schedule 2)
Trial: 23832397
Drug: MSC1992371A administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC1992371A administered on days 1-3 and 8-10 (schedule 3)
Trial: 20609183
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) at 1.8 g/day for 12 months
Trial: 16383032
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of 50 g/L CISS, 2,000 ml per day (Group A)
Trial: 16383032
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of 50 g/L glucose, 2,000 ml per day (Group B)
Trial: 12394711
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng (900 mg, 3 times daily)
Trial: 10088031
Drug: Levocabastine nasal
RxNorm normalized name: levocabastine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine nasal spray (0.2 mg twice daily)
Trial: 2259928
Drug: High-dose megestrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose megestrol acetate (800 mg per day)
Trial: 2259928
Drug: Standard-dose megestrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose megestrol acetate (160 mg per day)
Trial: 2259925
Drug: High-dose megestrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose megestrol acetate
Trial: 2259928
Drug: Standard-dose megestrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose megestrol acetate
Trial: 42529
Drug: Intranasal LH-RH
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal LH-RH
Trial: 19265745
Drug: Diaphragm plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragm plus placebo gel hydroxyethyl cellulose (HEC)
Trial: 19265745
Drug: Gel-diaphragm users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-diaphragm users
Trial: 19265745
Drug: Gel-only users
RxNorm normalized name: CALCIUM 0.8 ORAL TABLET [OnlyCal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-only users
Trial: 17479444
Drug: Combined T3/T4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined T3/T4 therapy
Trial: 11742168
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type-A (Botox) injection - 10 units to each side of the puborectalis or 20 units to the posterior aspect of this muscle.
Trial: 11742168
Drug: Further injections
RxNorm normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further injections of Botox (1-5 every 3 months) for those who did not respond to the first injection.
Trial: 9537613
Drug: Iron glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron glycine (1.4 mg added Fe/serving)
Trial: 9537613
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (1.4 mg added Fe/serving)
Trial: 8018689
Drug: 7 weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 weekly sessions on nutrition and behavior modification
Trial: 31591130
Drug: NTM-1634 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTM-1634 at 0.33 mg/kg
Trial: 31591130
Drug: NTM-1634 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTM-1634 at 0.66 mg/kg
Trial: 31591130
Drug: NTM-1634 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTM-1634 at 1 mg/kg
Trial: 26012700
Drug: Web-based prostate
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based prostate cancer treatment decision aid (DA) offered after diagnosis.
Trial: 18177867
Drug: 7.5 mg/day
RxNorm normalized name: nicotine 7.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/day letrozole
Trial: 18177867
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day clomiphene citrate (CC)
Trial: 17209177
Drug: Calcium +
RxNorm normalized name: Calcium + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium + Vitamin D supplement (600 mg elemental calcium and 200 IU vitamin D/tablet, 2 tablets/d)
Trial: 17209177
Drug: Calcium +
RxNorm normalized name: Calcium + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium + Vitamin D supplement
Trial: 14987190
Drug: Graded exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded exercise therapy programme
Trial: 26168681
Drug: Rengalin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rengalin (2 tablets 3 times daily for 3 days, then half dose for 4 days)
Trial: 26168681
Drug: Codelac (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codelac (1 tablet 3 times daily for 7 days)
Trial: 18381567
Drug: MC-1, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC-1, 250 mg/d
Trial: 12747229
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of 10 mg of dexamethasone phosphate in two doses at an interval of 12 hours
Trial: 346153
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (antifibrinolytic agent) for six weeks after rupture of an intracranial aneurysm
Trial: 346153
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antifibrinolytic treatment)
Trial: 31304912
Drug: Anaesthetic-analgesic ear
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthetic-analgesic ear drops
Trial: 28229980
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with oral iron supplementation
Trial: 28229980
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation with acupuncture
Trial: 28229980
Drug: Sham-acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-acupuncture combined with oral iron supplementation
Trial: 23807360
Drug: Human RV
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human RV vaccine (RIX4414)
Trial: 21849007
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) 15 mg qd (up-titrated to 30 mg after 6 weeks)
Trial: 21849007
Drug: Sitagliptin/Metformin (SITA/MET)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin/Metformin (SITA/MET) (up-titrated to 50/1000 mg bid over 4 weeks)
Trial: 21849007
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) (up-titrated to 45 mg qd)
Trial: 15005812
Drug: Psyllium-based supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium-based supplement (1 tablespoon with 8 oz of water, twice daily for 4 days)
Trial: 11355932
Drug: Blocking P‐glycoprotein‐mediated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blocking P‐glycoprotein‐mediated drug efflux
Trial: 7714551
Drug: PCNU 75-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCNU 75-100 mg/m2 IV every 8 weeks
Trial: 7714551
Drug: AZQ 15
RxNorm normalized name: AZQ
DrugBank: Diaziquone (DB17174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZQ 15 mg/m2 IV once a week for 4 weeks, every 6-8 weeks
Trial: 24353020
Drug: Red morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red morphine drops (RMD) - 1/12 of their 24-hour morphine dose
Trial: 24353020
Drug: Subcutaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous morphine (SCM) - 60 percent of their 24-hour morphine dose
Trial: 17645558
Drug: RSG/GLIM FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSG/GLIM FDC regimen A (4 mg/4 mg OD maximal)
Trial: 17645558
Drug: RSG/GLIM FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSG/GLIM FDC regimen B (8 mg/4 mg OD maximal)
Trial: 17645558
Drug: RSG (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSG (8 mg OD maximal)
Trial: 17645558
Drug: GLIM (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLIM (4 mg OD maximal)
Trial: 12800456
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS formulation
Trial: 8841156
Drug: Vancomycin therapeutic
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin therapeutic drug monitoring (TDM) group (n = 37)
Trial: 8841156
Drug: Vancomycin therapeutic
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin therapeutic drug monitoring (TDM)
Trial: 3154698
Drug: Molsidomine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (4 mg)
Trial: 1478400
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg) followed by Molsidomine (4 mg)
Trial: 2858145
Drug: Pancuronium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.01 mg/kg and Vecuronium 0.005 mg/kg
Trial: 2858145
Drug: Pancuronium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.01 mg/kg and Vecuronium 0.01 mg/kg
Trial: 2858145
Drug: Pancuronium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.01 mg/kg and Vecuronium 0.015 mg/kg
Trial: 25132158
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (50 mg.kg(‐1) followed by a continuous infusion of 15 mg.kg(‐1) .h(‐1))
Trial: 22584952
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g of chocolate containing 80% cacao
Trial: 20432513
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (donation-as-usual condition)
Trial: 12182385
Drug: Hib conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hib conjugate vaccine (HbOC)
Trial: 7801861
Drug: Colestipol 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol 10 g and lovastatin 20 mg/day (C10 + L20)
Trial: 7801861
Drug: Colestipol 5
RxNorm normalized name: colestipol 5 g oral granule for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol 5 g and lovastatin 20 mg/day (C5 + L20)
Trial: 7801861
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg/day (L40)
Trial: 7801861
Drug: Low-dose combinations
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combinations
Trial: 2139940
Drug: imipenem-cilastatin 500
RxNorm normalized name: imipenem-cilastatin 500 mg-500 mg injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imipenem-cilastatin 500 mg 8-hourly
Trial: 2139940
Drug: cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefotaxime 1 g 6-hourly combined with amikacin 5 mg/kg 8-hourly
Trial: 29561515
Drug: Lidocaine (0.2-0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (0.2-0.4 mg/kg) coadministered with amikacin (15 mg/kg)
Trial: 29561515
Drug: Amikacin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin (15 mg/kg) without lidocaine
Trial: 25454409
Drug: 3-item craving
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-item craving scale administered weekly
Trial: 22702067
Drug: GnRH analogues
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogues pre-treatment before laparoscopic myomectomy (LM)
Trial: 22702067
Drug: GnRH analogues
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogues pre-treatment before open laparotomic myomectomy (OM)
Trial: 22702067
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no pre-treatment) for laparoscopic myomectomy (LM)
Trial: 20580216
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate 12 microg twice-daily plus Tiotropium 18 microg once-daily (FOR-TIO)
Trial: 20580216
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate 12 microg twice-daily plus placebo (FOR-PLA)
Trial: 9121622
Drug: Transcranial magnetic
RxNorm normalized name: transcranial magnetic stimulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial magnetic stimulation (TMS) as add‐on therapy to standard antidepressive medication
Trial: 9121622
Drug: Standard antidepressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antidepressive medication only
Trial: 7117166
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of 5‐isosorbide mononitrate (5‐ISMN)
Trial: 7117166
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of 5‐isosorbide mononitrate (5‐ISMN)
Trial: 7117166
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of 5‐isosorbide mononitrate (5‐ISMN) three times daily for four weeks
Trial: 7117166
Drug: Chronic administration
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic administration of high doses of 5‐ISMN
Trial: 28509813
Drug: Fennel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fennel (100 mg, 2 capsules per day for 8 weeks)
Trial: 25975205
Drug: Variable dose
RxNorm normalized name: methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variable dose warfarin (target INR 2.0-2.5), treated for 28 ± 2 days
Trial: 25975205
Drug: Fixed low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed low-dose warfarin (1 mg daily starting 7 days preoperatively), treated for 28 ± 2 days
Trial: 25975205
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg daily starting on the day of surgery), treated for 28 ± 2 days
Trial: 24190687
Drug: Guided strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided strength training program (twice weekly for 19 weeks)
Trial: 21285171
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg eow